Zika virus antibody now available for research

Vanderbilt University, based in the US, has developed a Zika polyclonal antibody that recognises the human Zika envelope (E) protein and can be utilised for a range of applications to study the virus and its function. The university has now made the antibody available through life sciences company Kerafast.

“Progress in the field of infectious disease is predicated on the availability of critical reagents, many of which can be difficult to source,” noted Alan Bentley, head of the university’s Center for Technology Transfer & Commercialization. “We wanted to supply this Zika antibody to the global research community as quickly as possible.”

Through Kerafast’s online platform, the company facilitates accessibility to bioresearch materials from laboratories across the globe. The online collection is constantly being added to with new research materials that are available for purchase through a user-friendly and straightforward research-use-only ‘click licence’.

“At Kerafast, our mission promotes access to rare and unique research reagents by facilitating a community of both providing and procuring laboratories that work toward the cure of disease,” said Kerafast CEO Dr Robert Bondaryk. “We hope by making this Zika virus antibody available in our catalogue, we are helping to progress research toward a vaccine, treatment and cure for this worldwide health crisis.”

For more information on the antibody, visit the Kerafast website.

Image caption: The Anti-Zika Virus Envelope (E) Protein Antibody.